Novus Therapeutics begins phase 1 trial of OP0201 in otitis media
Novus Therapeutics has launched a phase 1 pharmacodynamics clinical trial for its promising candidate, OP0201, aimed at treating otitis media—a common middle ear infection. The California-based specialty pharmaceutical company, known for its focus on ENT (ear, nose, and throat) disorders, has begun dosing the first adult patients in the trial, named OP0201-C-001, which is taking […]